Top Players and Competitive Overview in the Glycomic Therapeutics Market

The glycomic therapeutics sector is poised for substantial expansion in the coming years, driven by advances in personalized medicine and innovative research. As new technologies and treatments emerge, this market is set to transform disease management and drug development significantly. Below is an overview of the market's size, key players, emerging trends, and segmentation details that highlight its promising future.

Forecasted Market Size Surge for the Glycomic Therapeutics Market by 2030
The glycomic therapeutics market is anticipated to grow rapidly, reaching a valuation of $424.67 billion by 2030. This represents a remarkable compound annual growth rate (CAGR) of 17.6% over the forecast period. Such growth is fueled by several critical factors including the increasing adoption of precision medicine, discoveries related to glycan biomarkers, the broadening pipeline of orphan drugs, pioneering advances in synthetic biology, and heightened investment in pharmaceutical research. Additionally, key trends shaping the market involve the expansion of glycan-based drug development, heightened focus on immune modulation therapies, growing application of enzyme replacement therapies, intensified research on rare and metabolic disorders, and rapid progress in synthetic glycan technologies.

Download a free report of the glycomic therapeutics market report:
https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Commanding the Glycomic Therapeutics Industry
Several prominent players dominate the glycomic therapeutics landscape, contributing to market innovation and growth. These include F Hoffmann-La Roche Ltd., Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ludger Ltd, and GlycoMar Limited. A notable development in the sector occurred in January 2027, when Japan's Kyowa Kirin Co., Ltd. acquired UK-based Orchard Therapeutics plc. The acquisition was aimed at bolstering Kyowa Kirin's expertise in rare and complex disease treatments by leveraging Orchard's gene therapy platform, which specializes in therapies for rare genetic disorders.

Emerging Trends Shaping the Future of Glycomic Therapeutics
Innovation remains a primary focus for key players in the medical device connectivity space, closely linked with glycomic therapeutics. These companies are pursuing AI-driven, cloud-based device connectivity solutions that unify data from various medical devices across care environments. This integration provides actionable insights, enhances operational efficiency, and supports more informed clinical decisions. The AI-powered platforms enable real-time analytics and enterprise-wide visibility, incorporating data from devices such as infusion pumps, patient monitors, and pharmacy robotics. For example, in October 2025, US-based medical technology firm BD (Becton, dic*kinson and Company) released the BD Incada Connected Care Platform in conjunction with their BD Pyxis Pro Automated Medication Dispensing Solution. This platform gathers data from nearly 3 million connected BD devices into a secure cloud ecosystem, offering clinicians customizable dashboards, natural language analytics, and comprehensive visibility into medication inventories. These capabilities help reduce waste, optimize workflows, and transform device data into practical insights for healthcare teams.

View the full glycomic therapeutics market report:
https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Comprehensive Segmentation of the Glycomic Therapeutics Market
The glycomic therapeutics market is segmented by class, structure, mode of action, and indications to provide a detailed understanding of its components:
1) By Class: Isolated, Synthetic
2) By Structures: Glycoproteins; Targeting Sialic Acid; Proteoglycans; Targeting Glycosaminoglycans; Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans; Targeting Glycosphingolipids; Other Structures
3) By Mode of Action: Neuraminidase inhibitors; inhibitors of heparanase and selectins; blockers of interactions between growth factors and heparan sulfate; erythropoietin and enzyme replacement therapy (ERT); tissue plasminogen activator; glucosylceramide synthase inhibitors; interleukins 1, 2, and 3; beta and gamma interferons; other modes of action
4) By Indications: Thrombosis and chemoprophylaxis; anemia; anti-adhesive and anti-inflammatory conditions; cataracts; Gaucher's disease; mucopolysaccharidosis (MPS-1 and IV); cancer; Alzheimer's disease; influenza types A and B; other indications

Further subdivisions include:
- For Isolated class: natural glycans, glycan derivatives, glycoproteins
- For Synthetic class: chemically synthesized glycans, recombinant glycans, glycopeptides

This detailed segmentation offers valuable insight into the diverse therapeutic approaches and applications driving advancements within the glycomic therapeutics market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.